Having trouble accessing articles? Reset your cache.

June 12 Company Quick Takes: Macao approves Zai's Zejula; plus Roche, NIH, CVS and Dassault-Medidata

Zai obtains Zejula's approval in Macao
Zai Lab Ltd. (NASDAQ:ZLAB) said it has received approval in Macao to market PARP inhibitor Zejula niraparib to treat ovarian cancer. Zai holds its local rights from the Tesaro Inc. unit of

Read the full 375 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE